March 13, 2013

Genzyme’s Multiple Sclerosis Franchise Featured at AAN

Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs

 

Genzyme’s Multiple Sclerosis Franchise Featured at AAN
Multiple Presentations Highlight Continuing Progress of AUBAGIO and LEMTRADA Programs

Paris, France – March 13, 2013 – Sanofi (EURONEXT: SAN and NYSE: SNY) and its subsidiary Genzyme announced today that data from its AUBAGIO® (teriflunomide) and LEMTRADATM (alemtuzumab) multiple sclerosis clinical development programs will be presented during the 65th American Academy of Neurology (AAN) Annual Meeting to be held in San Diego, Calif., March 16- 23.